Latest publication on employing “multi-omics” tools for an antibiotic-producing bacterium

A team of leading European companies and institutions, including NAICONS, recently reported a multi-omics study on the actinomycete Planobispora rosea [look at video and paper], producer of the antibiotic GE2270A. A derivative of this molecule has been licensed by NAICONS to Cassiopea SpA and is currently under Phase 2 clinical studies. Planobispora rosea is just one example of the thousands of unique, molecule-producing bacteria present in NAICONS’ strain collection. The study was financed by the EU H2020 program under the project TOPCAPI, underscoring the value of research grants for advancing NAICONS’ technology platform.